TAKEDA PHARMACEUTICAL CO LTD
TKPHFDrugs in Pipeline
92
Phase 3 Programs
72
Upcoming Catalysts
7
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
7 upcoming, 1 past
TDV
Healthy Volunteers
TVP-1012 1mg
Parkinson's Disease
Vedolizumab SC
Colitis, Ulcerative
Lapaquistat acetate
Hypercholesterolemia
TAK-788
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
TAP-144-SR(6M)
Premenopausal Breast Cancer
Glimepiride
Diabetic Patients
Teduglutide
Short Bowel Syndrome
Epoetin Alfa
Myelodysplastic Syndrome
Mezagitamab
Kidney Disease
Tetravalent Dengue Vaccine (TDV)
Dengue Fever
Pioglitazone and metformin
Diabetes Mellitus
TAK-881
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
omega-3-acid ethyl esters 90 (TAK-085)
Hypertriglyceridemia
TAK-625
Progressive Familial Intrahepatic Cholestasis (PFIC)
TAK-861
Narcolepsy Type 1
Lanadelumab
Hereditary Angioedema (HAE)
TAK-019
Coronavirus Disease (COVID-19)
Valsartan
Hypertension
Elritercept
Myelodysplastic Syndromes
Azilsartan medoxomil with or without add-on chlorthalidone
Hypertension
Ponatinib
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Glimepiride and Metformin
Diabetes Mellitus
Relugolix
Uterine Fibroids
Apremilast
Plaque Psoriasis
Bismuth-Containing Quadruple Therapy
Gastric Ulcer
Vedolizumab IV
Ulcerative Colitis
Vortioxetine
Depressive Disorder, Major
TAK-438
Duodenal Ulcer
Lansoprazole
Gastric Ulcers
Alogliptin
Type 2 Diabetes Mellitus
Pioglitazone
Diabetes Mellitus
Vedolizumab
Ulcerative Colitis
Zasocitinib
Plaque Psoriasis
Febuxostat
Hyperuricosuria
Pantoprazole
Gastroesophageal Reflux Disease (GERD)
Ramelteon
Chronic Insomnia
Metformin
Diabetes Mellitus
Lubiprostone
Chronic Idiopathic Constipation
Febuxostat IR
Gout
Lapaquistat acetate and atorvastatin
Dyslipidemia
TAK-360
Narcolepsy Type 2
Vonoprazan
Helicobacter Pylori
Alogliptin and insulin
Diabetes Mellitus
Alogliptin and metformin
Diabetes Mellitus
Trelagliptin 25 mg
Type 2 Diabetes Mellitus
Alogliptin and glimepiride
Type 2 Diabetes Mellitus
Allopurinol
Gout
Alogliptin 25 mg
Diabetes Mellitus
Duloxetine
Depressive Disorder, Major
IGI, 10%
Multiple Myeloma
Soticlestat
15q Duplication Syndrome
Alogliptin and voglibose
Type 2 Diabetes Mellitus
SYR-472
Type 2 Diabetes Mellitus
Dexlansoprazole MR
Esophagitis, Reflux
Dexlansoprazole
Gastroesophageal Reflux Disease (GERD)
TAK-771
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Fazirsiran Injection
Alpha1-Antitrypsin Deficiency
Ixazomib
Multiple Myeloma
Maribavir
Cytomegalovirus (CMV)
Azilsartan medoxomil
Hypertension
TAK-279
Ulcerative Colitis
Azilsartan medoxomil and chlorthalidone
Safety
Dexamethasone
Relapsed Multiple Myeloma
Chlorthalidone
Hypertension
Actovegin
Post-Stroke Cognitive Impairment (PSCI)
Darvadstrocel
Complex Perianal Fistulas in Adult Participants With Crohn's Disease
Azilsartan
Pediatric Hypertension
Lenalidomide
Relapsed Multiple Myeloma
TAK-928
IO-resistant sqNSCLC
TAK-875
Diabetes Mellitus
Alogliptin and pioglitazone
Type 2 Diabetes Mellitus
TAK-935
Epilepsy
TAK-583
Diabetic Neuropathies
NoV GI.1/GII.4 Bivalent VLP Vaccine
Healthy Volunteers
TAK-954
Diabetic Gastroparesis
TAK-755
Thrombotic Thrombocytopenic Purpura (TTP)
TAK-505
Malignant Solid Tumors
TAK-385
Endometriosis
Sitagliptin
Diabetes Mellitus, Type 2
Namilumab
Plaque Psoriasis
Peginesatide
Anemia
Rusfertide
Polycythemia Vera
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Colorectal Carcinoma
TAK-850
Influenza
Brentuximab Vedotin
Hodgkin Disease
Niraparib
Ovarian Cancer
TAK-079
Myasthenia Gravis
Idursulfase-IT
Hunter Syndrome
TAK-226
Myelodysplastic Syndromes
Cabozantinib
Advanced Hepatocellular Carcinoma
Voglibose
Diabetes Mellitus, Type 2
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TDV | Phase 3 | Healthy Volunteers | - | - |
TVP-1012 1mg | Phase 3 | Parkinson's Disease | - | - |
Vedolizumab SC | Phase 3 | Colitis, Ulcerative | - | - |
Lapaquistat acetate | Phase 3 | Hypercholesterolemia | - | - |
TAK-788 | Phase 3 | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | - | - |
TAP-144-SR(6M) | Phase 3 | Premenopausal Breast Cancer | - | - |
Glimepiride | Phase 3 | Diabetic Patients | - | - |
Teduglutide | Phase 3 | Short Bowel Syndrome | - | - |
Epoetin Alfa | Phase 3 | Myelodysplastic Syndrome | - | - |
Mezagitamab | Phase 3 | Kidney Disease | - | - |
Tetravalent Dengue Vaccine (TDV) | Phase 3 | Dengue Fever | - | - |
Pioglitazone and metformin | Phase 3 | Diabetes Mellitus | - | - |
TAK-881 | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | - | - |
omega-3-acid ethyl esters 90 (TAK-085) | Phase 3 | Hypertriglyceridemia | - | - |
TAK-625 | Phase 3 | Progressive Familial Intrahepatic Cholestasis (PFIC) | - | - |
TAK-861 | Phase 3 | Narcolepsy Type 1 | - | - |
Lanadelumab | Phase 3 | Hereditary Angioedema (HAE) | - | - |
TAK-019 | Phase 3 | Coronavirus Disease (COVID-19) | - | - |
Valsartan | Phase 3 | Hypertension | - | - |
Elritercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Azilsartan medoxomil with or without add-on chlorthalidone | Phase 3 | Hypertension | - | - |
Ponatinib | Phase 3 | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) | - | - |
Glimepiride and Metformin | Phase 3 | Diabetes Mellitus | - | - |
Relugolix | Phase 3 | Uterine Fibroids | - | - |
Apremilast | Phase 3 | Plaque Psoriasis | - | - |
Bismuth-Containing Quadruple Therapy | Phase 3 | Gastric Ulcer | - | - |
Vedolizumab IV | Phase 3 | Ulcerative Colitis | - | - |
Vortioxetine | Phase 3 | Depressive Disorder, Major | - | - |
TAK-438 | Phase 3 | Duodenal Ulcer | - | - |
Lansoprazole | Phase 3 | Gastric Ulcers | - | - |
Alogliptin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Pioglitazone | Phase 3 | Diabetes Mellitus | - | - |
Vedolizumab | Phase 3 | Ulcerative Colitis | - | - |
Zasocitinib | Phase 3 | Plaque Psoriasis | - | - |
Febuxostat | Phase 3 | Hyperuricosuria | - | - |
Pantoprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
Ramelteon | Phase 3 | Chronic Insomnia | - | - |
Metformin | Phase 3 | Diabetes Mellitus | - | - |
Lubiprostone | Phase 3 | Chronic Idiopathic Constipation | - | - |
Febuxostat IR | Phase 3 | Gout | - | - |
Lapaquistat acetate and atorvastatin | Phase 3 | Dyslipidemia | - | - |
TAK-360 | Phase 3 | Narcolepsy Type 2 | - | - |
Vonoprazan | Phase 3 | Helicobacter Pylori | - | - |
Alogliptin and insulin | Phase 3 | Diabetes Mellitus | - | - |
Alogliptin and metformin | Phase 3 | Diabetes Mellitus | - | - |
Trelagliptin 25 mg | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Alogliptin and glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Allopurinol | Phase 3 | Gout | - | - |
Alogliptin 25 mg | Phase 3 | Diabetes Mellitus | - | - |
Duloxetine | Phase 3 | Depressive Disorder, Major | - | - |
IGI, 10% | Phase 3 | Multiple Myeloma | - | - |
Soticlestat | Phase 3 | 15q Duplication Syndrome | - | - |
Alogliptin and voglibose | Phase 3 | Type 2 Diabetes Mellitus | - | - |
SYR-472 | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Dexlansoprazole MR | Phase 3 | Esophagitis, Reflux | - | - |
Dexlansoprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - | - |
TAK-771 | Phase 3 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | - | - |
Fazirsiran Injection | Phase 3 | Alpha1-Antitrypsin Deficiency | - | - |
Ixazomib | Phase 3 | Multiple Myeloma | - | - |
Maribavir | Phase 3 | Cytomegalovirus (CMV) | - | - |
Azilsartan medoxomil | Phase 3 | Hypertension | - | - |
TAK-279 | Phase 3 | Ulcerative Colitis | - | - |
Azilsartan medoxomil and chlorthalidone | Phase 3 | Safety | - | - |
Dexamethasone | Phase 3 | Relapsed Multiple Myeloma | - | - |
Chlorthalidone | Phase 3 | Hypertension | - | - |
Actovegin | Phase 3 | Post-Stroke Cognitive Impairment (PSCI) | - | - |
Darvadstrocel | Phase 3 | Complex Perianal Fistulas in Adult Participants With Crohn's Disease | - | - |
Azilsartan | Phase 3 | Pediatric Hypertension | - | - |
Lenalidomide | Phase 3 | Relapsed Multiple Myeloma | - | - |
TAK-928 | Phase 3 | IO-resistant sqNSCLC | - | - |
TAK-875 | Phase 3 | Diabetes Mellitus | - | - |
Alogliptin and pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - | - |
TAK-935 | Phase 2 | Epilepsy | - | - |
TAK-583 | Phase 2 | Diabetic Neuropathies | - | - |
NoV GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Healthy Volunteers | - | - |
TAK-954 | Phase 2 | Diabetic Gastroparesis | - | - |
TAK-755 | Phase 2 | Thrombotic Thrombocytopenic Purpura (TTP) | - | - |
TAK-505 | Phase 2 | Malignant Solid Tumors | - | - |
TAK-385 | Phase 2 | Endometriosis | - | - |
Sitagliptin | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Namilumab | Phase 2 | Plaque Psoriasis | - | - |
Peginesatide | Phase 2 | Anemia | - | - |
Rusfertide | Phase 2 | Polycythemia Vera | - | - |
oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Phase 2 | Colorectal Carcinoma | - | - |
TAK-850 | Phase 2 | Influenza | - | - |
Brentuximab Vedotin | Phase 2 | Hodgkin Disease | - | - |
Niraparib | Phase 2 | Ovarian Cancer | - | - |
TAK-079 | Phase 2 | Myasthenia Gravis | - | - |
Idursulfase-IT | Phase 2 | Hunter Syndrome | - | - |
TAK-226 | Phase 2 | Myelodysplastic Syndromes | - | - |
Cabozantinib | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
Voglibose | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in TAKEDA PHARMACEUTICAL CO LTD's drug pipeline?→
CatalystAlert tracks 92 drug candidates in TAKEDA PHARMACEUTICAL CO LTD's (TKPHF) pipeline across Phase 3, Phase 2. Its lead program is TDV (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TAKEDA PHARMACEUTICAL CO LTD's next FDA catalyst?→
TAKEDA PHARMACEUTICAL CO LTD's (TKPHF) next tracked catalyst is a Phase 2 expected July 21, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TKPHF biotech catalysts?→
Add TKPHF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TAKEDA PHARMACEUTICAL CO LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.